Literature DB >> 23396614

Predictive value of time-intensity curves obtained with contrast-enhanced ultrasonography (CEUS) in the follow-up of 30 patients with Crohn's disease.

F Giangregorio1, A Bertone, L Fanigliulo, G Comparato, G Aragona, M G Marinone, G Sbolli, P Tansini, F Fornari.   

Abstract

OBJECTIVES: CEUS can provide accurate quantitative estimates of intestinal wall microvascularization in Crohn's disease. We hypothesized that inflammation of the intestinal wall is correlated not with the amount of wall vascularization (study of vascularization patterns, SVP) but with the degree of wall flow during a period of time (time-intensity study, TIS). Our objective was to discover whether CEUS SPV and/or CEUS-TIS reflect(s) vascular inflammation of the intestinal wall and display(s) correlation with clinical activity of the disease at the time of the examination (T0) or at the 3- and 6-month follow-up (T3, T6).
MATERIALS AND METHODS: 30 patients with Crohn's disease (12 men, 18 women, mean age: 41.96 years; treatment: 5-ASA (n = 8), steroids (n = 13), anti-TNF (n = 7), azathioprine (n = 2) were studied with CEUS SPV and CEUS-TIS and followed for at least 6 months. The sonographic examinations were performed with SonoVue (BR1, Bracco) and a dedicated scanner (TECHNOS MPX, Esaote) equipped with software for calculation of time-intensity curves. Four vascular patterns (1: vascularization of the entire wall; 2: vascularization of >50% of the wall; 3: flow exclusively within the submucosal layer; 4: no signal). The semiquantitative analysis consisted in measurement of the area under the curve (AUC) (cut-off between active and inactive disease, 15), mean intesnity (IMA) (cut-off = 10). Each examination (180 s) was digitally recorded and analyzed.
RESULTS: T0: cDAI <150 in 22 pts; cDAI > 150 in 8; T3: 22 pts. with cDAI<150, 8 with cDAI >150. At T0 CEUS SPV and CEUS-TIS both displayed low specificity, diagnostic accuracy, and negative predictive values (p = ns). At T0, CEUS SPV produced 8 true positives (TP), 15 true negatives (TN), 8 false positives (FP), 0 false negative (FN) (sensitivity: 100%; specificity: 68.2%; diagnostic accuracy: 69.5%; Positive predictive value (PPV): 100%; negative predictive value (NPV: 53.3%), and CEUS-TIS produced 6 TP, 18 TN, 4 FP, 2 FN (sensitivity 75%; specificity: 81.8%; diagnostic accuracy: 75%; PPV: 60%; NPV: 90%). At T3, CEUS SPV produced 8 TP, 12 TN, 7 FP, 3 FN (sensitivity: 72.7%; specificity: 63.2%; diagnostic accuracy: 50%; PPV: 53.3%; NPV: 80%), and CEUS SIT produced the following results: 10 TP, 19 TN, 0 FP, 1 FN (sensitivity: 90,9%; specificity: 100%; diagnostic accuracy: 96,5%; PPV: 100%; NPV: 95%). At T3 CEUS-SVP displayed low sensitivity and low diagnostic accuracy, whereas SIT was able to predict clinical activity during follow-up in all but one case (which showed reactivation after 6 months) (p = 0.001)
CONCLUSION: CEUS-TIS alone was found to reflect vascular inflammation of the intestinal wall in Crohn's disease and predicted clinical activity during follow-up.

Entities:  

Keywords:  CDAI; CEUS; Contrast-enhanced ultrasonography; Crohn's disease; Disease activity; SonoVue; Ultrasonography

Year:  2009        PMID: 23396614      PMCID: PMC3553242          DOI: 10.1016/j.jus.2009.10.001

Source DB:  PubMed          Journal:  J Ultrasound        ISSN: 1876-7931


  42 in total

1.  Crohn disease activity evaluated by Doppler ultrasonography of the superior mesenteric artery and the affected small-bowel segments.

Authors:  Ensar Yekeler; Ahmet Danalioglu; Behzad Movasseghi; Sabri Yilmaz; Cetin Karaca; Sebahattin Kaymakoglu; Bulent Acunas
Journal:  J Ultrasound Med       Date:  2005-01       Impact factor: 2.153

Review 2.  New diagnostic imaging tools for inflammatory bowel disease.

Authors:  B A Mackalski; C N Bernstein
Journal:  Gut       Date:  2006-05       Impact factor: 23.059

3.  Contrast-enhanced ultrasonography with SonoVue after infliximab therapy in Crohn's disease.

Authors:  L Guidi; A De Franco; I De Vitis; A Armuzzi; S Semeraro; I Roberto; A Papa; E Bock; G Gasbarrini; G Fedeli
Journal:  Eur Rev Med Pharmacol Sci       Date:  2006 Jan-Feb       Impact factor: 3.507

Review 4.  Diagnostic efficacy of SonoVue.

Authors:  D Bokor
Journal:  Am J Cardiol       Date:  2000-08-17       Impact factor: 2.778

5.  Doppler sonography evaluation of superior mesenteric artery flow to assess Crohn's disease activity: correlation with clinical evaluation, Crohn's disease activity index, and alpha 1-antitrypsin clearance in feces.

Authors:  J A van Oostayen; M N Wasser; R A van Hogezand; G Griffioen; I Biemond; C B Lamers; A de Roos
Journal:  AJR Am J Roentgenol       Date:  1997-02       Impact factor: 3.959

Review 6.  Probiotics for maintenance of remission in Crohn's disease.

Authors:  V E Rolfe; P J Fortun; C J Hawkey; F Bath-Hextall
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 7.  Methotrexate for induction of remission in refractory Crohn's disease.

Authors:  A A F Alfadhli; J W D McDonald; B G Feagan
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

8.  Quantification of perfusion of liver tissue and metastases using a multivessel model for replenishment kinetics of ultrasound contrast agents.

Authors:  Martin Krix; Christian Plathow; Fabian Kiessling; Felix Herth; Andreas Karcher; Marco Essig; Harry Schmitteckert; Hans-Ulrich Kauczor; Stefan Delorme
Journal:  Ultrasound Med Biol       Date:  2004-10       Impact factor: 2.998

9.  CT of prominent pericolic or perienteric vasculature in patients with Crohn's disease: correlation with clinical disease activity and findings on barium studies.

Authors:  Seung Soo Lee; Hyun Kwon Ha; Suk-Kyun Yang; Ah Young Kim; Tae Kyoung Kim; Pyo Nyun Kim; Moon-Gyu Lee; Seung-Jae Myung; Hwoon-Yong Jung; Jin Ho Kim; Young Il Min
Journal:  AJR Am J Roentgenol       Date:  2002-10       Impact factor: 3.959

Review 10.  Doppler sonography in the diagnosis of inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Elia Armellini; Gino Roberto Corazza
Journal:  Dig Dis       Date:  2004       Impact factor: 2.404

View more
  7 in total

1.  The features of intestinal tuberculosis by contrast-enhanced ultrasound.

Authors:  Gaoyi Yang; Wenzhi Zhang; Tianzhuo Yu; Jun Meng; Dan Zhao; Xu Zhang; Jianping Xu; He Ning
Journal:  Jpn J Radiol       Date:  2015-07-15       Impact factor: 2.374

2.  Classification of contrast-enhanced ultrasonograms in rectal cancer according to tumor inhomogeneity using machine learning-based texture analysis.

Authors:  Yuan Luo; Lang-Kuan Qin; Jing-Wen Yan; Hao Yin; Hua Zhuang; Jie-Ying Zhao; Yu-Ting Wu; Zi-Qiang Wang; Xin Wang; Dong-Quan Liu
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 3.  Contrast-enhanced Ultrasound for Detection of Crohn's Disease Activity: Systematic Review and Meta-analysis.

Authors:  Zbigniew Serafin; Marcin Białecki; Agnieszka Białecka; Luca Maria Sconfienza; Maria Kłopocka
Journal:  J Crohns Colitis       Date:  2015-10-27       Impact factor: 9.071

4.  Dynamic contrast-enhanced ultrasound of the bowel wall with quantitative assessment of Crohn's disease activity in childhood.

Authors:  Damjana Kljucevsek; Dubravka Vidmar; Darja Urlep; Rok Dezman
Journal:  Radiol Oncol       Date:  2016-11-09       Impact factor: 2.991

Review 5.  Intestinal ultrasound and management of small bowel Crohn's disease.

Authors:  Torsten Kucharzik; Christian Maaser
Journal:  Therap Adv Gastroenterol       Date:  2018-05-01       Impact factor: 4.409

6.  Contrast-enhanced ultrasonography for the determination of Crohn's disease activity - preliminary experience.

Authors:  Marcin Białecki; Agnieszka Białecka; Katarzyna Laskowska; Maria Kłopocka; Ariel Liebert; Adam Lemanowicz; Zbigniew Serafin
Journal:  Pol J Radiol       Date:  2014-04-07

7.  Intraoperative cerebral glioma characterization with contrast enhanced ultrasound.

Authors:  Francesco Prada; Luca Mattei; Massimiliano Del Bene; Luca Aiani; Marco Saini; Cecilia Casali; Assunta Filippini; Federico Giuseppe Legnani; Alessandro Perin; Andrea Saladino; Ignazio Gaspare Vetrano; Luigi Solbiati; Alberto Martegani; Francesco DiMeco
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.